Search Medical Condition
Please enter condition
Please choose location from dropdown

Ferrol ( A Coruna), Spain Clinical Trials

A listing of Ferrol ( A Coruna), Spain clinical trials actively recruiting patients volunteers.

RESULTS

Found (19) clinical trials

Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With Ustekinumab

Study investigates benefit of treat to target maintenance treatment strategy versus routine care to test hypothesis that 'treat to target' ustekinumab (UST) maintenance treatment strategy coupled with early endoscopic assessment will result in higher endoscopic response rate after 48 weeks of treatment, compared to pragmatic maintenance treatment strategy. It consists ...

Phase

0.0 miles

Learn More »

This Study Observes the Use of New Oral Anticoagulants (NOACs) in Patients With a Heart Rhythm Disorder in Spain

The primary objective of the study is to describe the usage of NOACs in patients with NVAF, in the hospital setting, based on the baseline characteristics at the time of first NOAC initiation.

Phase N/A

1.12 miles

Learn More »

A Study of the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease

The purpose of this study is to evaluate the efficacy and safety of risankizumab versus placebo during induction therapy in subjects with moderately to severely active Crohn's disease (CD).

Phase

1.12 miles

Learn More »

A Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment

The objective of Study M15-991 is to evaluate the efficacy and safety of risankizumab versus placebo during induction therapy in subjects with moderately to severely active CD.

Phase

1.12 miles

Learn More »

Adalimumab Intralesional in Intestinal Strictures of Crohn's Disease Patients

We study if the administration of intralesional Adalimumab (directly injected in the stricture) associated to endoscopic dilatation has a higher success rate at week 8 compared with placebo in patients with Crohn's disease who had confirmed intestinal stenosis (3 stenosis as maximum)

Phase

1.12 miles

Learn More »

PROSABI: Prospective Multi-centre Study of Prognostic Factors in CRPC Patients Treated With Abiraterone Acetate.

This is a non-interventional prospective study in metastatic CRPC designed to explore biomarkers, composed by patients treated with Abiraterone Acetate. Key inclusion criteria: a) histological confirmation of prostate cancer; b) documented criteria (PCWG2) for CRPC; c) availability of tumour tissue; d) candidate for standard treatment with Abiraterone Acetate. Primary end ...

Phase N/A

1.12 miles

Learn More »

PROSENZA: Prospective Multi-Centre Study of Prognostic Factors in CRPC Patients Treated With Enzalutamide.

This is a non-interventional prospective study in metastatic CRPC designed to explore biomarkers, composed by patients treated with Enzalutamide. Key inclusion criteria: a) histological confirmation of prostate cancer; b) documented criteria (PCWG2) for CRPC; c) availability of tumour tissue; d) candidate for standard treatment with enzalutamide. Primary end point: to ...

Phase N/A

1.12 miles

Learn More »

PRORADIUM: Prospective Multi-centre Study of Prognostic Factors in CRPC Patients Treated With Radium-223.

This is a non-interventional prospective study in metastatic CRPC designed to explore biomarkers, composed by patients treated with Radium-223. Key inclusion criteria: a) histological confirmation of prostate cancer; b) documented criteria (PCWG2) for CRPC; c) availability of tumour tissue; d) candidate for standard treatment with Radium-223. Primary end point: to ...

Phase N/A

1.12 miles

Learn More »

Chart Review of Repatha in Subjects With Hyperlipidaemia

Review of clinical characteristics of patients who are prescribed Repatha and how their treatment is managed.

Phase N/A

1.12 miles

Learn More »

Study On Fatigue- And Hand-Foot Syndrome-Related Quality Of Life In Patients With Metastatic Renal Cell Carcinoma Receiving A Tyrosine Kinase Inhibitor as First-Line Treatment

Prospective, multicentre, observational study in patients with metastatic renal cell carcinoma (mRCC) receiving a tyrosine kinase inhibitor as first-line treatment according to routine clinical practice, designed to evaluate the incidence of fatigue and hand-foot syndrome in order to determine how these affect the baseline characteristics of the patient and his/her ...

Phase N/A

1.12 miles

Learn More »